Literature DB >> 21466748

Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.

F Schirmbeck1, C Esslinger, F Rausch, S Englisch, A Meyer-Lindenberg, M Zink.   

Abstract

BACKGROUND: Epidemiological investigations show that up to 30% of schizophrenic patients suffer from obsessive-compulsive symptoms (OCS) associated with negative impact on the general prognosis. It has been proposed that antiserotonergic second-generation antipsychotics (SGAs) might induce OCS, but investigations of large samples integrating psychopathology, neuropsychology and psychopharmacology are missing.
METHOD: We stratified 70 patients with schizophrenia according to their mode of antipsychotic treatment: clozapine and olanzapine (group I) compared with aripiprazole and amisulpride (group II). The groups were matched according to age, sex, educational levels and severity of the psychotic disorder (Positive and Negative Syndrome Scale). As the primary endpoint, we evaluated OCS severity (Yale-Brown Obsessive-Compulsive Scale).
RESULTS: OCS were significantly more prevalent and severe in group I, in which OCS severity correlated with dosage of clozapine and duration of treatment. Pronounced cognitive deficits in group I were found in visuospatial perception and visual memory (Wechsler Adult Intelligence Scale-Revised block design, Rey-Osterrieth Complex Figure Test), impulse inhibition (go/no-go test), higher perseveration scores (Wisconsin Card Sorting Test) and reduced set-shift abilities (Trail Making Test Part B, Set-shift Task). These cognitive domains correlated with OCS severity.
CONCLUSIONS: OCS in schizophrenia are associated with antiserotonergic SGA treatment, but longitudinal studies have to prove causality. Before starting treatment with antiserotonergic SGAs, specific neurocognitive domains should be evaluated, as visuospatial learning and impulse inhibition performance might allow early detection of OCS secondary to antipsychotic treatment in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466748     DOI: 10.1017/S0033291711000419

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  28 in total

1.  Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.

Authors:  Frederike Schirmbeck; Daniela Mier; Christine Esslinger; Franziska Rausch; Susanne Englisch; Sarah Eifler; Andreas Meyer-Lindenberg; Peter Kirsch; Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2015-03       Impact factor: 6.186

2.  Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment

Authors:  David D. Kim; Alasdair M. Barr; Randall F. White; William G. Honer; Ric M. Procyshyn
Journal:  J Psychiatry Neurosci       Date:  2019-01-01       Impact factor: 6.186

Review 3.  Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.

Authors:  Trehani M Fonseka; Margaret A Richter; Daniel J Müller
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

Review 4.  Obsessive-Compulsive Symptoms in Schizophrenia: an Up-To-Date Review of Literature.

Authors:  Chloé Tezenas du Montcel; Antoine Pelissolo; Franck Schürhoff; Baptiste Pignon
Journal:  Curr Psychiatry Rep       Date:  2019-07-01       Impact factor: 5.285

5.  Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study.

Authors:  Frederike Schirmbeck; Franziska Rausch; Susanne Englisch; Sarah Eifler; Christine Esslinger; Andreas Meyer-Lindenberg; Mathias Zink
Journal:  Schizophr Bull       Date:  2012-10-27       Impact factor: 9.306

6.  Transition from Obsession to Delusion in Schizo-obsessive Disorder: A Case Report and Literature Overview.

Authors:  Estêvão Scotti-Muzzi; Osvaldo Luis Saide
Journal:  Innov Clin Neurosci       Date:  2018-08-01

7.  Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms.

Authors:  Jun Cai; Wen Zhang; Zhenghui Yi; Weihong Lu; Zhiguo Wu; Jun Chen; Shunying Yu; Yiru Fang; Chen Zhang
Journal:  Psychopharmacology (Berl)       Date:  2013-05-10       Impact factor: 4.530

8.  Impulsivity in disorders of food and drug misuse.

Authors:  T B Mole; M A Irvine; Y Worbe; P Collins; S P Mitchell; S Bolton; N A Harrison; T W Robbins; V Voon
Journal:  Psychol Med       Date:  2014-08-14       Impact factor: 7.723

9.  Role of aripiprazole in treatment-resistant schizophrenia.

Authors:  Nilufar Mossaheb; Rainer M Kaufmann
Journal:  Neuropsychiatr Dis Treat       Date:  2012-05-29       Impact factor: 2.570

10.  Frequency of obsessive-compulsive disorder in patients with multiple sclerosis: A cross-sectional study.

Authors:  Mohsen Foroughipour; Fatemeh Behdani; Paria Hebrani; Majid Nabizadeh Marvast; Fereshte Esmatinia; Amir Akhavanrezayat
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.